logo
  

Gerresheimer AG Increases Its Revenue, Adj. EBITDA Guidance - Quick Facts

Gerresheimer AG (GRRMF.PK) reaffirmed its growth agenda and increased its revenue and adjusted EBITDA guidance. The guidance for fiscal 2023, for group level, FXN, include: organic revenue growth: at least 10%; organic adjusted EBITDA growth: at least 10%; and adjusted EPS growth: low-single digit.

For mid-term, for group level, FXN, guidance includes: organic revenue growth: at least 10%; organic adjusted EBITDA margin: of 23-25%; and adjusted EPS growth: at least 10%.

Dietmar Siemssen, CEO of Gerresheimer AG, said: "Our formula g strategy process is paying off and generating sustainable growth across all our divisions. With new orders for High Value Solutions and Medical Devices, we have further reinforced our leading positions in attractive markets. We will continue to shift the portfolio from volume to value and expand our margins."

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
RELATED NEWS
Follow RTT